IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study

被引：0

作者：

Shu, J. ^{[1
]}

Zhu, T. ^{[2
]}

Huang, Y. ^{[3
]}

Xu, Q. ^{[4
]}

Guo, R. ^{[5
]}

Liu, H. ^{[6
]}

Zhao, H. ^{[7
]}

Zhu, L. ^{[8
]}

Wang, X. ^{[9
]}

Xu, X. ^{[10
]}

Cheng, W. ^{[11
]}

Tang, J. ^{[12
]}

Zhu, Q. ^{[13
]}

Chen, X. ^{[14
]}

An, R. ^{[15
]}

Gao, J. ^{[16
]}

Li, G. ^{[17
]}

Zhang, Z. ^{[18
]}

Zhou, H. ^{[19
]}

Zhou, Q. ^{[20
]}

机构：

[1] Chongqing Univ, Affiliated Canc Hosp, Dept Gynecol, Chongqing, Peoples R China

[2] Zhejiang Canc Hosp, Gynaecol Oncol, Hangzhou, Peoples R China

[3] Hubei Canc Hosp, Gynecol Oncol, Wuhan, Peoples R China

[4] Fujian Prov Canc Hosp, Dept Gynecol Oncol, Fuzhou, Peoples R China

[5] Zhengzhou Univ, Affiliated Hosp 1, Gynaecol Oncol Dept, Zhengzhou, Peoples R China

[6] Gansu Prov Hosp, Gynecol Dept, Lanzhou, Peoples R China

[7] Shanxi Canc Hosp, Gynaecol Oncol Dept, Taiyuan, Peoples R China

[8] Nanjing Univ, Oncol Dept, Nanjing Drum Tower Hosp, Sch Med, Nanjing, Peoples R China

[9] Xuzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[10] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Gynecol Oncol, Beijing, Peoples R China

[11] Jiangsu Prov Hosp, Gynecol Dept, Nanjing, Peoples R China

[12] Hunan Canc Hosp, Gynecol Oncol, Changsha, Peoples R China

[13] Jiangxi Maternal & Child Hlth Care Hosp, Dept Oncol, Nanchang, Jiangxi, Peoples R China

[14] Fudan Univ, Dept Oncol, Jiangxi Maternal & Child Hlth Care Hosp, Shanghai, Peoples R China

[15] Xi An Jiao Tong Univ, Affiliated Hosp 1, Gynecol Dept, Xian, Peoples R China

[16] Jiangxi Canc Hosp, Dept Gynecol Oncol, Nanchang, Jiangxi, Peoples R China

[17] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gynecol & Oncol, Union, NJ USA

[18] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang, Peoples R China

[19] Innovent Biol Suzhou Co Ltd, Med Oncol, Suzhou, Peoples R China

[20] Chongqing Univ, Affiliated Canc Hosp, Gynecol Oncol, Chongqing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

720MO

引用

页码：S551 / S551

页数：1

共 50 条

[11] Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
Yingying Xu
Yakun Wang
Jifang Gong
Xiaotian Zhang
Zhi Peng
Xinan Sheng
Chenyu Mao
Qingxia Fan
Yuxian Bai
Yi Ba
Da Jiang
Fen Yang
Changsong Qi
Jian Li
Xicheng Wang
Jun Zhou
Ming Lu
Yanshuo Cao
Jiajia Yuan
Dan Liu
Zhenghang Wang
Jianmin Fang
Lin Shen
Gastric Cancer, 2021, 24 : 913 - 925
[12] MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.
Zambrano, Cristina Cruz
Almhanna, Khaldoun
Messersmith, Wells A.
Ahnert, Jordi Rodon
Ryan, David P.
Faris, Jason Edward
Jung, JungAh
Fasanmade, Adedigbo
Wyant, Tim
Kalebic, Thea
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[13] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma
Hwu, P.
Sznol, M.
Pavlick, A.
Kluger, H.
Kim, K. B.
Boasberg, P.
Sanders, D.
Simantov, R.
Crowley, E.
Hamid, O.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[14] Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
Xu, Yingying
Wang, Yakun
Gong, Jifang
Zhang, Xiaotian
Peng, Zhi
Sheng, Xinan
Mao, Chenyu
Fan, Qingxia
Bai, Yuxian
Ba, Yi
Jiang, Da
Yang, Fen
Qi, Changsong
Li, Jian
Wang, Xicheng
Zhou, Jun
Lu, Ming
Cao, Yanshuo
Yuan, Jiajia
Liu, Dan
Wang, Zhenghang
Fang, Jianmin
Shen, Lin
GASTRIC CANCER, 2021, 24 (04) : 913 - 925
[15] Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours
Zhang, Jian
Liu, Rujiao
Gao, Shuiping
Li, Wenhua
Chen, Yang
Meng, Yanchun
Liu, Chang
Jin, Wenyue
Wu, Junyan
Wang, Ying
Hao, Yanrong
Yi, Shuli
Qing, Yan
Ge, Junyou
Hu, Xichun
NPJ BREAST CANCER, 2023, 9 (01)
[16] Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985
Van Herpen, C. M.
Banerji, U.
Mommers, E. C.
Koper, N. P.
Goedings, P.
Lopez, J.
Awada, A.
Fiebrich, H. B.
Aftimos, P. G.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S65 - S65
[17] A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+breast cancer (BC)
Beeram, M.
Burris, H. A., III
Modi, S.
Birkner, M.
Girish, S.
Tibbitts, J.
Holden, S. N.
Lutzker, S. G.
Krop, I. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[18] A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
Le Joncour, Vadim
Martins, Ana
Puhka, Maija
Isola, Jorma
Salmikangas, Marko
Laakkonen, Pirjo
Joensuu, Heikki
Barok, Mark
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (10) : 1721 - 1730
[19] Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Ott, Patrick A.
Hamid, Omid
Pavlick, Anna C.
Kluger, Harriet
Kim, Kevin B.
Boasberg, Peter D.
Simantov, Ronit
Crowley, Elizabeth
Green, Jennifer A.
Hawthorne, Thomas
Davis, Thomas A.
Sznol, Mario
Hwu, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) : 3659 - +
[20] A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.
Meric-Bernstam, Funda
Calvo, Emiliano
Moreno, Victor
Chung, Hyun Cheol
Park, Yeon Hee
Bang, Yung-Jue
Rosen, Lee S.
Mita, Monica M.
Garrido-Laguna, Ignacio
Leung, Abraham C. F.
Dube, Harman
Zhong, Wei
Chen, Xiaoying
Dawaher, Rula
Curigliano, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →